Français

Acasti Pharma Inc.

  • English
  • About Us
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • CaPre®
    • TRILOGY Phase 3
    • Partnering
  • Our Science
  • News & Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Results
    • Stock Data
    • Regulatory Filings
    • Governance
  • Contact
  • Français

Press Releases

News & Investors

News & Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Media
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • NASDAQ: ACST
    • TSXV: ACST
    • Analyst Coverage
  • Regulatory Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Section 16 Filings
    • SEDAR
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News / Events

  • Overview
  • Press Releases
  • Media
  • IR Calendar
  • Email Alerts

Acasti Pharma Announces Annual Performance Grants of Stock Options, Amendment of Stock Option Plan and Issuance of Common Shares in Payment of Outstanding Interest under Debentures

Jul 2, 2018

Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018

Jun 27, 2018

Acasti Pharma Reports on Positive Feedback Following Today’s Presentation at the XVIII International Symposium on Atherosclerosis

Jun 11, 2018

Acasti Pharma to Present at the XVIII(th) International Symposium on Atherosclerosis

Jun 6, 2018

Acasti Pharma Appoints Brian Groch as Chief Commercial Officer

Jun 4, 2018

Acasti Pharma Retains Crescendo Communications for Investor Relations Services in the United States

May 18, 2018

Acasti Pharma Appoints Donald Olds to its Board of Directors and Audit Committee

Apr 27, 2018

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

Apr 2, 2018

Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia

Mar 14, 2018

Acasti Pharma Reports Third Quarter FY 2018 Financial Results

Feb 13, 2018
RSS
  • Prev
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • ...20
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2021 Acasti Pharma Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap